Pipeline › ecnoglutide
ecnoglutide
Not FDA-approved, and in phase 3 development, not authorised in the European Union. 4 active trials, the next due to complete 2026-11-30.
GLP-1 agonist, SC, from Sciwind Biosciences. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase3
- Target
- GLP-1
- Route
- SC
- Sponsor
- Sciwind Biosciences
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 4 (3 in phase 3)
- Participants enrolled
- 760
- Trials with a reporting date
- 4
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-08-31 | Status changed | A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) NCT07734311 · Hangzhou Sciwind Biosciences Co., Ltd. | Not yet recruiting → Recruiting | P3 |
When these trials report
Next 4 of 4 active trials by estimated primary completion.
Indications under study
Knee Osteoarthritis; OSA - Obstructive Sleep Apnea; Obesity; Overweight; Weight Maintenance.
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2026-07-07 | Ecnoglutide: First Approvals Shirley M. | Drugs |
| 2026-06-17 | Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants Li F, Du C, Yu Q, Feng S, Cai L, Chen Z, Zou Q, Guo W, Du D, Hu F, Liu X, Huang Y, Shi S, Shi W, Guan L, Yang L, Zheng Q, Li Y, Liu R, Yang M. | Diabetes Obes Metab |
| 2026-05-01 | Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis Kumar M, Kumar S, Ali SME, Qazi H, Janjua AA, Ahmed H, Babar R, Sheikh RI, Kumar L, Ali SM, Hanif F, Gul K, Ali AS, Bukhari SUR, Raja A, Chaulagain A. | Endocrinol Diabetes Metab |
| 2026-04-29 | No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study Chen Z, Du C, Cai L, Feng S, Zou Q, Guo W, Li F, Du D, Hu F, Liu X, Huang Y, Shi S, Shi W, Yu Q, Zhang L, Guan L, Yang L, Li Y, Liu R, Ning J, Yang M, Zheng Q. | Front Pharmacol |
| 2026-01-07 | Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, Lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Bing S, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. | Nat Commun |
| 2025-08-22 | Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management? Scheen AJ. | Lancet Diabetes Endocrinol |
| 2025-08-22 | Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y, Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X. | Lancet Diabetes Endocrinol |
| 2025-06-21 | Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. | Lancet Diabetes Endocrinol |
| 2025-05-22 | Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a randomised, double-blind, placebo-controlled, phase 3 trial Bing s, Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. | Research Square preprint |
| 2024-09-27 | Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial Zhu D, Wang W, Tong G, Ma G, Ma J, Han J, Zhang X, Liu Y, Gan S, Qin H, Zheng Q, Ning J, Zhu Z, Guo M, Bu Y, Li Y, Jones CL, Fenaux M, Junaidi MK, Xu S, Pan H. | Nat Commun |
| 2023-06-24 | Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, Li F, Li Y, Feng J, Zhu Z, Zheng Q, Zhu R, Wang B, Li Y, Hao S, Qin H, Jones CL, Adegbite E, Telusca L, Fenaux M, Zhong W, Junaidi MK, Xu S, Pan H. | Mol Metab |